Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2022 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly

BURNABY, British Columbia, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
March 21, 2022 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics Closes USD$12M Equity Financing

BURNABY, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...
March 16, 2022 13:37 ET | Source: ACCESS Health International

Dr. William Haseltine releases new book on Innate Immunity and Covid-19

New York, March 16, 2022 (GLOBE NEWSWIRE) -- In his latest book, bestselling author William A. Haseltine Ph.D. tells us that understanding our natural immunity to the SARS-CoV-2 virus is critical...
January 11, 2022 15:00 ET | Source: Enterin Inc.

Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function

PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
June 23, 2021 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu’s First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment

VANCOUVER, British Columbia, June 23, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
June 09, 2021 09:00 ET | Source: Qu Biologics, Inc.

Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021

VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
May 12, 2021 09:00 ET | Source: Qu Biologics, Inc.

Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasis

VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...